BioCryst Pharmaceuticals Ratios and Metrics

Market cap in millions MXN. Fiscal year is January - December.

Millions MXN. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 15, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	37,757	29,566	32,457	20,740	41,746	51,090
Market Cap Growth	1.22%	-8.91%	56.49%	-50.32%	-18.29%	95.19%
Enterprise Value	41,243	38,031	43,128	28,311	47,499	53,366
Last Close Price	118.00	159.50	155.00	113.92	215.00	255.00
PE Ratio	7.95	6.22	-	-	-	-
PS Ratio	2.40	1.88	3.46	3.70	7.90	15.86
PB Ratio	-17.60	-13.78	-3.27	-2.69	-7.26	-23.29
P/FCF Ratio	6.08	4.76	-	-	-	-
P/OCF Ratio	6.04	4.73	-	-	-	-
EV/Sales Ratio	2.74	2.42	4.59	5.05	8.99	16.56
EV/EBITDA Ratio	6.96	6.06	-	-	-	-
EV/EBIT Ratio	7.03	6.08	-	-	-	-
EV/FCF Ratio	6.64	6.13	-	-	-	-
Debt / Equity Ratio	-4.01	-4.01	-1.77	-1.86	-2.52	-5.54
Debt / EBITDA Ratio	1.36	1.36	371.00	-	-	-
Debt / FCF Ratio	1.38	1.38	-	-	-	-
Net Debt / Equity Ratio	-1.70	-1.70	-1.09	-1.01	-1.08	-0.80
Net Debt / EBITDA Ratio	0.58	0.58	-15774.79	-4.73	-2.17	-0.48
Net Debt / FCF Ratio	0.59	0.59	-9.79	-4.72	-1.94	-0.59
Asset Turnover	1.74	1.74	0.90	0.62	0.48	0.34
Inventory Turnover	26.83	26.83	10.10	7.70	12.00	18.93
Quick Ratio	1.95	1.95	2.49	2.97	4.50	5.18
Current Ratio	2.06	2.06	2.63	3.31	4.89	5.46
Return on Assets (ROA)	43.21%	43.21%	-0.16%	-11.57%	-16.30%	-24.07%
Return on Invested Capital (ROIC)	413.47%	535.23%	-5.24%	-738.74%	-24821.91%	-
Return on Capital Employed (ROCE)	109.20%	109.20%	-0.40%	-26.90%	-33.40%	-36.70%
Earnings Yield	12.58%	16.07%	-5.71%	-18.47%	-11.55%	-7.39%
FCF Yield	16.45%	21.00%	-3.41%	-7.93%	-7.63%	-5.80%
Buyback Yield / Dilution	-5.75%	-5.75%	-7.54%	-3.38%	-3.79%	-7.08%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.